ROCÍO
GARCÍA CARBONERO
Profesora asociada de Ciencias de la Salud
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (11)
2021
-
Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2019
-
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131
-
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer
Cancer Chemotherapy and Pharmacology
2018
-
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study
Annals of Oncology, Vol. 29, Núm. 3, pp. 602-609
-
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set
ESMO Open, Vol. 3, Núm. 3
-
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
British Journal of Cancer, Vol. 119, Núm. 10, pp. 1208-1214
2017
-
Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
European Journal of Cancer, Vol. 78, pp. 61-69
-
Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial
Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608
2016
-
Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI
Annals of Oncology, Vol. 27, pp. vi198
-
Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
Annals of Oncology, Vol. 27, Núm. 11, pp. 2082-2089
2015
-
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508